skip to main content

Pseudoephedrine sale restrictions — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

HardPharmacy Law and EthicsPseudoephedrine sale restrictionsGPhC CRA

A man taking mycophenolate mofetil is stopping treatment. His female partner could become pregnant and uses no other teratogenic medicine. Which contraception advice is current?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: CUse reliable contraception during treatment and for at least 90 days after his final dose

Explanation lettering: D = shown as B · B = shown as D

A ends precautions too early. B incorrectly applies the six-week interval used in advice for female patients taking mycophenolate and overstates the number of methods required here. C is correct: either the treated male patient or his female partner should use reliable contraception during treatment and for at least 90 days after stopping. D wrongly restricts responsibility to the male patient and shortens the interval. E is wrong because the precaution concerns potential paternal exposure even when the partner does not take mycophenolate.

Reference: MHRA: updated contraception advice for male patients taking mycophenolate. https://www.gov.uk/drug-safety-update/mycophenolate-mofetil-mycophenolic-acid-updated-contraception-advice-for-male-patients